George M Whitesides
CIK 1233438 · last filed 2021-04-29
George M Whitesides is a corporate insider who has filed 35 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for TBPH, was dated Apr 29, 2021. Across all open-market trades the lifetime net is +$98.8K, making them a net buyer over the disclosed history. 15 SEC filings were submitted jointly with Innoviva, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TBPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
61 MOONEY STREET
CAMBRIDGE, MA 02138
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) Delisted | Director | 37,478 | $17.03 | $638.3K | $98.8K | 8 | 2021-04-29 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | Director | 1,101 | $0.70 | $771 | $0 | 2 | 2020-05-06 |
| Innoviva, Inc. (THRX) Delisted | Director | 770,695 | $4.06 | $3.13M | $0 | 10 | 2014-03-10 |
| ROHM & HAAS CO (ROH) Delisted | Director | 11,916 | — | — | $0 | 14 | 2009-03-04 |
Recent Filings
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-04-29 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +9,828 | $0 | EDGAR |
| 2020-05-06 | Lyra Therapeutics, Inc. (LYRA) Delisted | Conv (C) | +6,404 | $0 | EDGAR |
| 2020-05-01 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | +19,661 | $314.6K | EDGAR |
| 2020-04-30 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +6,635 | $0 | EDGAR |
| 2019-05-02 | Theravance Biopharma, Inc. (TBPH) Delisted | Mixed | −12,627 | $0 | EDGAR |
| 2018-05-03 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +8,186 | $0 | EDGAR |
| 2017-08-14 | Theravance Biopharma, Inc. (TBPH) Delisted | Buy (P) | +4,000 | $98.8K | EDGAR |
| 2017-05-18 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +6,000 | $0 | EDGAR |
| 2016-05-05 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +6,000 | $0 | EDGAR |
| 2015-04-24 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +6,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.